Earnings ·
BillionToOne reports Q3 revenue of $123.0M and raises full-year guidance to $460M-$470M
BLLNBillionToOne, Inc.
BillionToOne reported third-quarter 2026 total revenue of $123.0 million, a 47% increase from the prior year period, driven by strong growth in prenatal clinical testing revenue of $104.3 million and oncology revenue of $17.1 million. The company delivered 206,000 tests during the quarter, up 25% year-over-year, while maintaining a gross profit margin of 71%. Net income reached $17.4 million, or $0.32 per diluted share, compared to $1.5 million in the same period last year. Additionally, BillionToOne raised its full-year 2026 revenue guidance to a range of $460 million to $470 million, representing 51% to 54% growth over 2025. The company operates as a next-generation molecular diagnostics firm developing accessible and accurate genetic tests.